AstraZeneca Hopes Bydureon Pen Will Rewrite GLP-1 Story
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approved an easier-to-use pen version of Bydureon for the treatment of type 2 diabetes, but AstraZeneca will need to move quickly and effectively with the launch if it is to establish the brand before other long-acting GLP-1’s enter the market.
You may also be interested in...
Lilly Prices Trulicity Near Victoza, But Well Above Tanzeum
Easy-to-use pen with invisible needle to deliver Lilly’s GLP-1 agonist dulaglutide is an asset compared to delivery of other once-weeklies in the class, but the crowded market is still very challenging.
Price Is GSK’s Weapon Ahead Of Tanzeum Launch
GlaxoSmithKline has priced its once-weekly GLP-1 agonist Tanzeum 64% below the high dose of Novo Nordisk’s market-leading, once-daily Victoza – a sign of the uphill commercial battle it faces against an entrenched rival.
Price Is GSK’s Weapon Ahead Of Tanzeum Launch
GlaxoSmithKline has priced its once-weekly GLP-1 agonist Tanzeum 64% below the high dose of Novo Nordisk’s market-leading, once-daily Victoza – a sign of the uphill commercial battle it faces against an entrenched rival.